Press releases

November 11, 2019

The National Accreditation Program for Breast Centers (NAPBC), a quality program of the American College of Surgeons (ACS), has granted a three-year accreditation to Cancer Treatment Centers of America® (CTCA) Chicago in Zion, Illinois for the...

September 24, 2019

With more than three decades of healthcare experience, most recently as CEO of St. Christopher’s Hospital for Children, Maria Scenna steps into leadership position with national oncology network.

September 19, 2019

Independence Blue Cross (Independence), the leading health insurer in southeastern Pennsylvania, and Cancer Treatment Centers of America (CTCA) Philadelphia, part of a national network of cancer care providers, have signed a new four-year agreement....

July 30, 2019

Cancer Treatment Centers of America® (CTCA) Chicago has been named a High Performing Hospital in Lung Cancer Surgery by U.S. News & World Report.

June 25, 2019

Cancer Treatment Centers of America® (CTCA), Chicago, has honored CTCA® Chicago nurse, Mike Stimac, RN with the DAISY Award for Extraordinary Nurses in recognition for his commitment and patient-centered approach to care. The award is part of the...

June 24, 2019

Cancer Treatment Centers of America® (CTCA), Chicago has named Adrienne Schultz, MSN, RN, HN-BC, vice president of patient care services and chief nursing officer. Schultz previously served as assistant vice president of patient care services at...

June 17, 2019

In March, the National Comprehensive Cancer Network (NCCN) released updated guidelines stating that Heated Intraperitoneal Chemotherapy (HIPEC) using the chemotherapy drug cisplatin can be considered with debulking surgery for stage III epithelial...

June 14, 2019

April 23, 2019

Cancer Treatment Centers of America® (CTCA) Chicago has honored CTCA® Chicago nurse, Julie Rout, RN BSN OCN, with the DAISY Award for Extraordinary Nurses in recognition for her commitment and patient-centered approach to care.

April 23, 2019

Physicians at Cancer Treatment Centers of America® (CTCA) Chicago have a new option in the fight against rare neuroendocrine tumors (NETs) with the introduction of an innovative therapy called lutetium Lu 177 dotatate (Lutathera®).